Domus Diagnostics Moves Closer to Delivering Affordable At-Home Molecular Test for COVID-19, Flu-A, Flu-B and RSV
The award, up to $2.4M through the NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, will support accelerated validation and scaling of Domus Diagnostics' testing platform for clinical trial readiness.
- The award, up to $2.4M through the NIH’s Rapid Acceleration of Diagnostics (RADx®) Tech program, will support accelerated validation and scaling of Domus Diagnostics' testing platform for clinical trial readiness.
- The Domus Diagnostics' platform is an ultra-low cost, zero-power testing platform that will produce novel devices that enable user-friendly, accurate, and effective infectious disease testing at home, in doctors’ offices, or in community testing facilities.
- The devices will provide a significantly more affordable and accessible global option for infectious disease testing.
- The Domus technology doesn’t require any instrumentation, electricity, or even batteries to run – making it a zero-power testing solution.